{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Fulcrum Therapeutics Announces CEO Transition - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"hdI8pFil15\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-announces-ceo-transition\/\">Fulcrum Therapeutics Announces CEO Transition<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/fulcrum-therapeutics-announces-ceo-transition\/embed\/#?secret=hdI8pFil15\" width=\"600\" height=\"338\" title=\"&#8220;Fulcrum Therapeutics Announces CEO Transition&#8221; &#8212; Market Newsdesk\" data-secret=\"hdI8pFil15\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"\u2013 Robert J. Gould, Ph.D. announces retirement; will continue to serve as board member and advisor \u2013 \u2013 Bryan E. Stuart promoted to president and chief executive officer effective March 31, 2021 \u2013 CAMBRIDGE,\u00a0Mass., March 04, 2021 (GLOBE NEWSWIRE) &#8212; Fulcrum Therapeutics, Inc.\u00a0(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Bryan E. Stuart, the company\u2019s chief operating officer, will become Fulcrum\u2019s president and chief executive officer and will be appointed to the Board of Directors. Mr. Stuart will succeed current president and chief executive officer Robert J. Gould, Ph.D. who will be retiring as of March 31, 2021. Dr. Gould will remain as a member of the &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDExMyM0MDQ3NjY2IzIxODM1NDI="}